Jeffrey H. Lipton
Expertise in
12
conditions

Jeffrey H. Lipton

55 Harbord St, M5S 2 W6, 
Toronto, ON, CA 
Expertise in
12
conditions
55 Harbord St, M5S 2 W6, 
Toronto, ON, CA 

Overview

Jeffrey Lipton practices practicing medicine in Toronto, Canada.

Mr. Lipton is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Pure Red Cell Aplasia, Aase Syndrome, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 271 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

55 Harbord St, M5S 2 W6, Toronto, ON, Canada
Other Locations
9200 W Wisconsin Ave, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY
A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY
Enrollment Status: Completed
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

271 Total Publications

Jewish Tradition and Patient Communication.
Jewish Tradition and Patient Communication.
Journal: The Israel Medical Association journal : IMAJ
Published: September 06, 2026

Frequently Asked Questions about Jeffrey H. Lipton

Is Jeffrey H. Lipton a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Jeffrey H. Lipton is classified as an Elite expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jeffrey H. Lipton participate in research or clinical trials?

Yes. Jeffrey H. Lipton has published 271 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Jeffrey H. Lipton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lipton's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile